Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: An economic analysis

Vaccine

Volumn 25, Issue 42, 2007, Pages 7307-7312

  Hammerschmidt, Thomas ^a   Bisanz, Helmtrud ^a   Wutzler, Peter ^b  

^a GLAXOSMITHKLINE   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Economics; Germany; Vaccination; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHICKENPOX; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; ECONOMIC ASPECT; GERMANY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; MEASLES; MUMPS; PRIORITY JOURNAL; RUBELLA; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST SAVINGS; GERMANY; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; MASS VACCINATION; MEASLES-MUMPS-RUBELLA VACCINE; MODELS, ECONOMIC; MODELS, STATISTICAL; SENSITIVITY AND SPECIFICITY; VACCINES, COMBINED;

EID: 34748886651     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.017     Document Type: Article

References (26)

1. Robert Koch-Institute. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI)/Stand: Januar 2000 [Vaccination recommendation of the Standing Committee on Vaccinations (STIKO)/Status: January 2000]. Epidemiol Bull 2 (2000) 9-20
2. Wutzler P., Farber I., Wagenpfeil S., Bisanz H., and Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 20 1-2 (2001) 121-124
3. Robert Koch-Institute. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI)/Stand: Juli 2001 [Vaccination recommendation of the Standing Committee on Vaccinations (STIKO)/Status: July 2001]. Epidemiol Bull 28 (2001) 203-218
4. Wagenpfeil S., Neiss A., Banz K., and Wutzler P. Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect 10 5 (2004) 425-430
5. Ziebold C., von Kries R., Lang R., Weigl J., and Schmitt H.J. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics 108 5 (2001) E79 Erratum: Pediatrics 2004 May;113(5):1470
6. Banz K., Wagenpfeil S., Neiss A., Goertz A., Staginnus U., Vollmar J., et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21 11-12 (2003) 1256-1267
7. Coudeville L., Brunot A., Szucs T.D., and Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 8 3 (2005) 209-222
8. Nguyen H.Q., Jumaan A.O., and Seward J.F. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352 5 (2005) 450-458
9. Seward J.F., Watson B.M., Peterson C.L., Mascola L., Pelosi J.W., Zhang J.X., et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287 5 (2002) 606-611
10. Robert Koch-Institute. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI)/Stand: Juli 2004 [Vaccination recommendation of the Standing Committee on Vaccinations (STIKO)/Status: July 2004]. Epidemiol Bull 30 (2004) 235-250
11. Hammerschmidt T., Goertz A., Wagenpfeil S., Neiss A., Wutzler P., and Banz K. Validation of health economic models: the example of EVITA. Value Health 6 5 (2003) 551-559
12. Robert Koch-Institue. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI)/Stand: Januar 2006 [Vaccination recommendation of the Standing Committee on Vaccinations (STIKO)/Status: July 2006]. Epidemiol Bull 30 (2006) 235-254
13. Varis T., and Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174 Suppl. 3 (1996) S330-S334
14. Kroger A.T., Atkinson W.L., Marcuse E.K., and Pickering L.K. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-15 (2006) 1-48
15. Arvin A., and Gershon A. Control of varicella: why is a two-dose schedule necessary?. Pediatr Infect Dis J 25 6 (2006) 475-476
16. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23 2 (2004) 132-137
17. Lieu T.A., Black S.B., Ray G.T., Martin K.E., Shinefield H.R., and Weniger B.G. The hidden costs of infant vaccination. Vaccine 19 1 (2000) 33-41
18. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care 9 Suppl. 1 (2003) S6-S12
19. Marcy S.M. Pediatric combination vaccines: their impact on patients, providers, managed care organizations, and manufacturers. Am J Manag Care 9 4 (2003) 314-320
20. Kalies H., Grote V., Verstraeten T., Hessel L., Schmitt H.J., and von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 25 6 (2006) 507-512
21. Kalies H., Grote V., Schmitt H.J., and von Kries R. Immunisation status of children in Germany: temporal trends and regional differences. Eur J Pediatr 165 1 (2006) 30-36
22. Thiry N., Beutels P., Van Damme P., and Van Doorslaer E. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21 1 (2003) 13-38
23. Brisson M., and Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 88 10 (2003) 862-869
24. Brisson M., and Edmunds W.J. The cost-effectiveness of varicella vaccination in Canada. Vaccine 20 7-8 (2002) 1113-1125
25. Goldman G.S. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Vaccine 23 25 (2005) 3349-3355
26. Wagenpfeil S., Neiss A., and Wutzler P. Effects of varicella vaccination on herpes zoster incidence. Clin Microbiol Infect 10 11 (2004) 954-960